Quick Facts: Therapeutic Domains

• An established component in the treatment of certain cancers, often used in combination with other agents.
• Used for the management of advanced gastric cancer.
• Utilized in adjuvant chemotherapy for certain stages of colorectal cancer.

---

Tegafur is a medication used in the management of specific cancer types. It is an established component of the treatment plan for adults with advanced gastric cancer when administered in combination with cisplatin. This combination therapy is intended to help address the progression of the condition.

The medication is also utilized in the adjuvant setting for colorectal cancer, specifically following curative surgical procedures. In this context, the therapy is used to manage the risk of disease recurrence, particularly in certain high-risk patients with resected rectal or colon cancer. Tegafur, often used in a combination product (such as with uracil or gimeracil/oteracil), helps support the overall therapeutic strategy against the disease. These agents are part of regimens designed to deliver sustained management of the condition.

Regulatory References

1. EMA therapeutic overview for combination therapies

Official Population Eligibility and Restrictions

Tegafur’s eligibility for use is defined strictly by regulatory authorities and is established primarily for adults for its approved indications. Official regulatory documents outline specific conditions and populations for whom use is prohibited or restricted.

---

Absolute Contraindications

The medicine is contraindicated in patients with a known complete deficiency of the dihydropyrimidine dehydrogenase (DPD) enzyme, which is essential for safe metabolism. Use is also strictly prohibited in pregnant women and those who are breastfeeding. Further contraindications include patients with severe bone marrow suppression, End-Stage Renal Disease (ESRD) requiring dialysis, or a history of severe reactions to any fluoropyrimidine drug.

Age and Organ Status Limitations

Use is not established and not recommended in children and adolescents under 18 years of age. Eligibility is conditional for certain patients with moderate renal impairment (Creatinine Clearance 30 to 50 mL/min), a group for whom use is restricted and requires regulatory dose modification.

Tegafur Interactions with other medicines and products

The official regulatory profile for Tegafur, a prodrug of 5-Fluorouracil (5-FU), identifies several clinically significant interaction constraints, primarily centered on the enzyme Dihydropyrimidine Dehydrogenase (DPD), which is responsible for breaking down 5-FU.

---

Contraindicated Combinations

Co-administration with specific medications and substances is strictly prohibited:

• Brivudine and Analogues: Co-administration with the antiviral brivudine or its chemically related analogues is contraindicated due to the high risk of severe toxicity from increased 5-FU exposure. Treatment with Tegafur is also prohibited for at least four weeks following the last dose of these DPD inhibitors.
• Other Fluoropyrimidines: The combination of Tegafur-containing products with other fluoropyrimidines (such as 5-FU or capecitabine) is contraindicated.
• DPD Deficiency: Use is contraindicated in patients with a known complete DPD deficiency because the lack of this enzyme leads to life-threatening accumulation of the active drug.

---

Exposure-Modifying and DPD-Related Interactions

The most frequent formulation of Tegafur is combined with gimeracil, which is included to cause an intended interaction by reversibly inhibiting DPD. This action enhances and sustains the systemic exposure of the active 5-FU metabolite.

Administration Timing Constraint

To manage drug exposure, the medication must be taken with water at least 1 hour before or 1 hour after a meal, as specified in the official regulatory documentation.

Population-Specific Notes

Patients with identified partial DPD deficiency are officially noted as being at an increased risk for toxicity and require consideration for a reduced starting dose as part of the regulatory guidance.

Primary Mechanism: Inhibition of Genetic Replication

Tegafur is a prodrug that is converted into the active metabolite 5-Fluorouracil (5-FU), which acts as a fraudulent building block. The 5-FU metabolite binds irreversibly to the enzyme Thymidylate Synthase (TS), a critical step that blocks the synthesis of DNA precursors. This molecular interference corrupts both DNA and RNA, causing cell cycle arrest and inducing apoptosis in high-turnover cells.

---

Systemic Enhancement and Clearance Modulation

The combination therapy includes Gimeracil, an inhibitor of Dihydropyrimidine Dehydrogenase (DPD), the body's primary enzyme for breaking down 5-FU. By blocking DPD, Gimeracil sustains higher and more prolonged systemic concentrations of the active 5-FU in the circulation. This modulation of the clearance pathway ensures that the cytotoxic mechanism has an extended window of action.

---

Mechanism for Differential Tissue Sparing

The combination also utilizes Oteracil to achieve a degree of differential cytotoxic effect. Oteracil concentrates in the gastrointestinal mucosa, where it inhibits the enzyme OPRT, which is required to activate 5-FU. This localized blockade reduces the formation of the active cytotoxic substance in healthy, rapidly dividing cells of the gut lining, resulting in attenuated localized activation.

How Tegafur is Used

The administration of tegafur, typically prescribed as a component of a fixed-dose combination product (e.g., S-1), adheres to strict, standardized protocols.

---

Official Administration Guidelines

Parameter	Instruction
Route of Administration	The medicine is administered orally as hard capsules.
Dosing Schedule	The standard dose is calculated based on the patient's Body Surface Area (BSA) (m^2). The typical starting dose is mathbf25 mg/m^2 (tegafur content) per dose, taken twice daily.
Frequency and Timing	Administration is twice daily (morning and evening) in a cyclic pattern of 21 consecutive days of dosing, followed by a 7-day rest period.
Meal Timing	Capsules must be taken with water and specifically at least one hour before or one hour after a meal.

---

Procedural Context and Adjustments

The usage protocol is based on the 28-day cycle that is repeated over the course of treatment. The prescription and management of this regimen must be overseen by a physician with expertise in oncology. Administration rules also specify criteria for patient populations and handling non-adherence:

• Dose Reduction: Protocols detail specific, non-reversible dose reduction steps (e.g., to mathbf20 mg/m^2) for managing administration-related issues; doses cannot be increased again once reduced.
• Renal Impairment: A specific standard dose reduction (e.g., to mathbf20 mg/m^2) is required for patients with moderate renal impairment.
• Missed or Omitted Doses: Doses omitted due to toxicity or if a patient vomits after administration should not be replaced within the cycle.
• Pediatric Use: Safety and efficacy have not been established for the pediatric population, and use in patients under 18 years is not recommended.

Research Evidence / Overview of Studies for Tegafur

---

Evidence for Use in Colorectal Cancer

Tegafur was studied for use in combination with other substances like leucovorin (folinic acid) for the evaluation of colorectal cancer treatment. The research base comes from Phase III Randomized Controlled Trials (RCTs) and meta-analyses that research examined in two primary clinical contexts.

For patients with advanced or metastatic colorectal cancer, research explored how oral Tegafur regimens compared to intravenous (IV) chemotherapy regimens. These studies monitored time-to-event outcomes (such as Overall Survival (OS) and Progression-Free Survival (PFS)). Studies reported measurements of OS and PFS comparing the oral regimen to the IV standards.

In the adjuvant setting—meaning after curative surgery for Stage II or Stage III colorectal or colon cancer—trials compared the use of the oral Tegafur regimen against the standard IV regimen. The primary outcomes research examined were Disease-Free Survival (DFS), which measures the duration of time without cancer recurrence, and Overall Survival. These studies contribute to the broader evidence landscape by providing context on how the oral regimen was evaluated in the post-operative setting.

---

Evidence for Use in Gastric Cancer

Tegafur was studied for use in evaluating advanced gastric cancer, primarily as a component of specific combination regimens (such as S-1, which contains two other substances). These studies explored populations with advanced or metastatic gastric cancer, as well as those with Stage II or Stage III gastric cancer receiving treatment after curative surgery. Key outcomes research examined included Overall Survival (OS), Progression-Free Survival (PFS), and the Objective Response Rate (ORR), which tracks tumor size changes over time.

---

What is Still Uncertain About Tegafur Research

While a substantial research base exists, certain aspects of the Tegafur evidence landscape are still emerging. Comparative evidence is lacking for Tegafur used as a single agent in gastric cancer, as nearly all high-level data involve specific combination products. Furthermore, the evidence quality varies across studies when trying to draw conclusions about its direct comparison to other chemotherapy combinations that have been developed since the main trials were conducted. The results apply only to the populations studied, and long-term effects are not fully established beyond the observation periods of the primary RCTs.

Key Studies & References

1. Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis

Common questions about Tegafur (FAQ)

Q: Is Tegafur given alone or is it always used in combination with other drugs?

A: Tegafur is a core compound that is typically formulated and studied as a combination product with other agents, such as Gimeracil and Oteracil. This design helps to enhance the medicine's effects and may reduce potential toxicity to the gut lining. While Tegafur is a single component, it is usually not administered as a single-agent treatment.

Q: Can Tegafur affect a person's fertility, in both men and women?

A: Official regulatory documents indicate that this medication may cause genotoxicity, which means it has the potential to be harmful to reproductive cells. For this reason, effective contraceptive measures are generally recommended for both male and female patients during therapy and for a specified period (e.g., 6 months) following the last dose.

Q: Is it safe to get a vaccination while being treated with Tegafur?

A: As with many chemotherapy agents, the effectiveness of vaccines may be affected while a patient is undergoing treatment. Official information and clinical data suggest that this medication does not necessarily reduce the efficacy of certain vaccines. Regulatory information and clinical data should be consulted regarding the timing of vaccinations while on therapy.

Q: Are there any restrictions on driving or operating heavy machinery while taking Tegafur?

A: Official product information advises patients to be aware of potential side effects that can affect concentration and motor skills. If patients experience adverse effects such as dizziness or confusion (which are signs of potential nervous system effects), they should refrain from driving or operating heavy machinery.

Q: What are the common skin changes, like rashes or dry skin, seen with Tegafur?

A: Official reports indicate that the medicine can be associated with skin and subcutaneous tissue disorders. These documented effects include common issues like rashes, pruritus (itching), and other serious skin reactions.

Q: Is it possible for Tegafur to affect heart function?

A: Official regulatory warnings note that cardiotoxicity (harmful effects on the heart) has been associated with fluoropyrimidine therapy, the class of drugs to which Tegafur belongs. This includes reports of serious events such as myocardial infarction (heart attack) and arrhythmias (irregular heartbeat).

Q: Is the risk of side effects higher when Tegafur is used in combination with Cisplatin?

A: Tegafur is often administered in combination with drugs like Cisplatin for its approved uses. Official protocols involve frequent monitoring of lab tests, such as blood cell counts and kidney function, to help manage the risks associated with combination therapy and ensure proper dose adjustment.

Q: Is it safe to consume alcohol in moderation while on Tegafur treatment?

A: Official regulatory guidance generally recommends avoiding alcohol consumption while taking this medication. This is due to the potential for increased risk of liver damage when alcohol is combined with this type of chemotherapy.

Q: Does Tegafur increase the risk of developing a blood clot?

A: While the regulatory documents do not specifically list 'blood clots' as a common side effect, the medicine is associated with a risk of cardiovascular events. As a fluoropyrimidine, it belongs to a class of drugs that are generally associated with a potential for vascular toxicity.

Q: Can Tegafur cause eye problems like increased tearing or conjunctivitis?

A: Yes, official product information confirms that the medicine can lead to ocular disorders (eye problems). These documented effects include lacrimal disorders (excessive tearing or watering eyes) and signs of conjunctivitis (inflammation of the eye).

Q: Is it possible to experience symptoms like confusion or other neurological effects?

A: Yes, official safety information indicates that the medication is associated with nervous system disorders. Documented reports include neurological effects such as confusion, dizziness, and signs of cerebellar syndrome (e.g., problems with coordination).

Q: Does Tegafur affect a patient's blood sugar levels?

A: Regulatory documents indicate that patients with diabetes or other glucose-related issues require close monitoring of their blood sugar levels throughout the course of treatment with this medication.

Storage and Disposal of Tegafur

Tegafur, as a component of combination therapies, must be stored under specific environmental conditions to maintain stability, adhering to regulations for cytotoxic agents.

Official Storage Requirements

Condition	Requirement
Temperature	Store below 30 C (86°F).
Prohibited Storage	Do not refrigerate or freeze.
Protection	Protect from moisture and light.
Container Rule	Keep in the original container.

Handling and Disposal

This medicine must be kept out of the sight and reach of children. Due to its classification as a hazardous medicinal product, disposal of unused or expired Tegafur must strictly follow local hazardous waste requirements. It must not be disposed of via wastewater or household waste. In the event a capsule is broken, established protocols for handling cytotoxic products must be observed.